Enliven Therapeutics, Inc. Cost of Goods Sold (COGS)
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
| Cost of Goods Sold (COGS) | $0.0 | $0.0 | $33.0K | $97.0K | $99.0K | $622.0K | $297.0K |
Enliven Therapeutics, Inc. (ELVN) Cost of Goods Sold (COGS) comparison analysis
General
LTM Cost of Goods Sold (COGS)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
ELVN key stats
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.6 | 0.3 |
% margin | 0.0 0.0% | 0.0 0.0% | (0.0) 0.0% | (0.1) 0.0% | (0.1) 0.0% | (0.6) 0.0% | (0.3) 0.0% |
| Operating Expenses | 8.9 | 10.7 | 24.1 | 9.3 | 24.8 | 38.8 | 83.5 |
| Research & Development Expenses (R&D) | 7.9 | 8.2 | 19.0 | 8.2 | 20.5 | 31.0 | 64.6 |
| Selling, General & Administrative Expenses (SG&A) | 1.0 | 2.4 | 5.1 | 1.1 | 4.3 | 7.8 | 19.0 |
% margin | (8.9) 0.0% | (10.7) 0.0% | (24.1) 0.0% | (9.3) 0.0% | (24.8) 0.0% | (38.8) 0.0% | (83.5) 0.0% |
| Interest Income | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | 1.1 | 12.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | 0.2 | (11.3) | (23.5) | (19.0) | (24.7) | (37.7) | (71.6) |
% effective tax rate | 0.2 100.0% | (0.8) 7.2% | 0.7 (2.8%) | (0.0) 0.2% | (0.0) 0.1% | 0.1 (0.2%) | 0.0 0.0% |
% margin | 0.0 0.0% | (11.3) 0.0% | (23.5) 0.0% | (18.9) 0.0% | (24.7) 0.0% | (37.8) 0.0% | (71.6) 0.0% |
| EPS | 0.00 | (2.62) | (5.43) | (14.14) | (3.17) | (6.03) | (2.01) |
| Diluted EPS | 0.00 | (2.62) | (5.43) | (14.14) | (3.17) | (6.03) | (2.01) |
% margin | 0.2 0.0% | (11.3) 0.0% | (23.4) 0.0% | (9.3) 0.0% | (24.6) 0.0% | (38.6) 0.0% | (81.9) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Enliven Therapeutics, Inc.'s Cost of Goods Sold (COGS)?
As of today, Enliven Therapeutics, Inc.'s last 12-month Cost of Goods Sold (COGS) is $235.0K, based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Enliven Therapeutics, Inc.'s Cost of Goods Sold (COGS) growth rate?
Over the last year, Enliven Therapeutics, Inc.'s Cost of Goods Sold (COGS) growth was 6.8%. The average annual Cost of Goods Sold (COGS) growth rates for Enliven Therapeutics, Inc. have been 111.0% over the past three years, N/A over the past five years.
3) Is Enliven Therapeutics, Inc.'s Cost of Goods Sold (COGS) growth rate Good?
Over the last year, Enliven Therapeutics, Inc.'s Cost of Goods Sold (COGS) growth was 6.8%, which is higher than industry growth of (0.3%). It indicates that Enliven Therapeutics, Inc.'s Cost of Goods Sold (COGS) growth is Good.